Entero Healthcare Solutions (ENTERO) investor relations material

Executive summary

• H1 FY27 revenue was Rs 40,275.70 million, up 35.4% YoY; LFL growth was 37.2%, including 19.8% organic growth.

• Q2FY27 LFL revenue grew 34.7% YoY, with EBITDA margin at 5.3%; management expects to exceed FY27 growth and margin guidance, with no revised targets.

• Growth reflected organic expansion, calendarisation of prior-year acquisitions and rising MedTech contribution; no acquisitions were completed in H1, according to management.

Financial highlights

• Q2 revenue was Rs 20,870.75 million; EBITDA was Rs 110.7 crore, up 78% YoY, and gross profit was Rs 240.0 crore, up 49%.

• Q2 net profit was Rs 607.42 million, up 66% YoY; profit attributable to owners was Rs 455.43 million, up 44%.

• H1 EBITDA was Rs 207.7 crore, up 85%; net profit was Rs 1,127.93 million, up 69%, and profit attributable to owners was Rs 837.05 million, up 41%.

• Q2 basic EPS was Rs 10.47; H1 basic EPS was Rs 19.24.

Outlook and guidance

• FY27 guidance remains ~23% consolidated revenue growth excluding new acquisitions, 5% EBITDA margin and 50% EBITDA-to-operating-cash-flow conversion; management expects to outperform growth and margin targets.

• FY27 MedTech revenue is expected to exceed Rs 1,000 crore; current activity focuses on IVD and cardiology/orthopedic devices.

• Acquisition calendarisation is expected to taper in Q3 and further in Q4 absent new deals; opportunities remain under evaluation.